Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioage Labs Inc (BIOA)

Bioage Labs Inc (BIOA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 503,045
  • Shares Outstanding, K 35,855
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,110 K
  • EBIT $ -90 M
  • EBITDA $ -90 M
  • 60-Month Beta 1.38
  • Price/Sales 108.27
  • Price/Cash Flow N/A
  • Price/Book 1.81

Options Overview Details

View History
  • Implied Volatility 145.26% (+50.38%)
  • Historical Volatility 111.37%
  • IV Percentile 20%
  • IV Rank 12.24%
  • IV High 826.12% on 04/04/25
  • IV Low 50.29% on 09/17/25
  • Expected Move (DTE 3) 3.49 (19.52%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 227
  • Volume Avg (30-Day) 58
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 1,450
  • Open Int (30-Day) 1,326
  • Expected Range 14.37 to 21.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.01
  • Number of Estimates 2
  • High Estimate -0.75
  • Low Estimate -1.27
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.87 +50.42%
on 01/05/26
17.90 -0.28%
on 01/12/26
+4.97 (+38.59%)
since 12/12/25
3-Month
5.04 +254.17%
on 10/17/25
17.90 -0.28%
on 01/12/26
+12.50 (+233.64%)
since 10/10/25
52-Week
2.88 +519.79%
on 04/09/25
17.90 -0.28%
on 01/12/26
+12.91 (+261.34%)
since 01/10/25

Most Recent Stories

More News
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in...

BIOA : 17.85 (+27.23%)
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity economy is entering a massive repricing event as researchers confirm that metabolic dysfunction...

LGVN : 0.5719 (-8.25%)
AVAI : 0.5850 (+14.73%)
BIOA : 17.85 (+27.23%)
GAA : 33.17 (+0.17%)
DNLI : 17.95 (+5.09%)
MAPT : 0.0003 (unch)
KLTO : 0.3388 (+0.21%)
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β,...

BIOA : 17.85 (+27.23%)
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...

BIOA : 17.85 (+27.23%)
BioAge Labs to Present at Jefferies Global Healthcare Conference in London

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...

BIOA : 17.85 (+27.23%)
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates

First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end Continued advancement of oral and parenteral APJ agonist programs...

BIOA : 17.85 (+27.23%)
BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...

BIOA : 17.85 (+27.23%)
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development...

BIOA : 17.85 (+27.23%)
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement...

BIOA : 17.85 (+27.23%)
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

BIOA : 17.85 (+27.23%)

Business Summary

BioAge Labs Inc. is a clinical-stage biopharmaceutical company. It involved in developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging. BioAge Labs Inc. is based in RICHMOND, Calif.

See More

Key Turning Points

3rd Resistance Point 21.86
2nd Resistance Point 19.88
1st Resistance Point 18.86
Last Price 17.85
1st Support Level 15.87
2nd Support Level 13.89
3rd Support Level 12.88

See More

52-Week High 17.90
Last Price 17.85
Fibonacci 61.8% 12.16
Fibonacci 50% 10.39
Fibonacci 38.2% 8.62
52-Week Low 2.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar